Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A11 | P48066 | 5/20 | 0.47 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.47 |
| ▸ | KIF11 | P52732 | 2/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | CASR | P41180 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.42 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3700787 | 0.86 | L3MBTL1 (0.47) | SLC6A11SLC6A1CASRALDH1A1NPC1 | |
| SCHEMBL4421178 | 0.86 | HDAC6 (0.47) | SLC6A11SLC6A1MEN1KMT2AALDH1A1 | |
| SCHEMBL3689532 | 0.84 | MTNR1B (0.43) | SLC6A11SLC6A1KIF11NPC1RAB9A | |
| SCHEMBL23777331 | 0.82 | SLC6A11 (0.47) | SLC6A11SLC6A1MEN1KMT2ATP53 | |
| SCHEMBL28468939 | 0.82 | TAS1R3 (0.38) | KIF11CNR1CNR2CASRKMT2A | |
| SCHEMBL3690284 | 0.82 | KIF11 (0.50) | SLC6A11SLC6A1KIF11MEN1KMT2A | |
| SCHEMBL3695302 | 0.81 | SLC6A11 (0.48) | SLC6A11SLC6A1KIF11MEN1KMT2A | |
| SCHEMBL8633174 | 0.80 | KIF11 (0.48) | SLC6A11SLC6A1KIF11MEN1KMT2A | |
| SCHEMBL14762445 | 0.80 | SMN1; SMN2 (0.45) | SLC6A11SLC6A1KIF11CASRMEN1 | |
| SCHEMBL3691998 | 0.79 | TGM2 (0.45) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117957022-A | Antisense compounds and methods for targeting CUG repeats | 安卓达治疗股份有限公司 | 2024-04-30 | — | — | CN | disclosed |
| CN-117915957-A | Compositions and methods for modulating mRNA splicing | 恩特拉达治疗学股份有限公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-117897176-A | Compositions and methods for modulating tissue distribution of intracellular therapeutic agents | 恩特拉达治疗学股份有限公司 | 2024-04-16 | — | — | CN | disclosed |
| CN-117561271-A | Cyclic cell penetrating peptides | 恩特拉达治疗公司 | 2024-02-13 | — | — | CN | disclosed |
| CN-114901253-A | Improved lipid nanoparticles for delivery of nucleic acids | 爱康泰生治疗公司 | 2022-08-12 | — | — | CN | disclosed |
| EP-2081949-B1 | TRIPARTITE OLIGONUCLEOTIDE COMPLEXES AND METHODS FOR GENE SILENCING BY RNA INTERFERENCE | GE HEALTHCARE DHARMACON INC (US) | 2014-12-10 | — | — | EP | disclosed |
| US-8809514-B2 | Tripartite oligonucleotide complexes and methods for gene silencing by RNA interference | GE HEALTHCARE DHARMACON, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| EP-2760477-A1 | DI-ALIPHATIC SUBSTITUTED PEGYLATED LIPIDS | Alnylam Pharmaceuticals, Inc. (US) | 2014-08-06 | — | — | EP | disclosed |
| WO-2013049328-A9 | DI-ALIPHATIC SUBSTITUTED PEGYLATED LIPIDS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-12-27 | — | — | WO | disclosed |
| EP-2663548-A1 | PEGYLATED LIPIDS AND THEIR USE FOR DRUG DELIVERY | Alnylam Pharmaceuticals, Inc. (US) | 2013-11-20 | — | — | EP | disclosed |
| WO-2012016184-A2 | METHODS AND COMPOSITIONS FOR DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | WO | disclosed |
| WO-2011143230-A1 | METHODS AND COMPOSITIONS FOR DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS (US) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011075656-A1 | METHODS AND COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2011-06-23 | — | — | WO | disclosed |
| WO-2011036557-A1 | COMPOSITIONS AND METHODS FOR ENHANCING CELLULAR UPTAKE AND INTRACELLULAR DELIVERY OF LIPID PARTICLES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2011-03-31 | — | — | WO | disclosed |
| US-20100093085-A1 | TRIPARTITE OLIGONUCLEOTIDE COMPLEXES AND METHODS FOR GENE SILENCING BY RNA INTERFERENCE | DHARMACON, INC (US) | 2010-04-15 | — | — | US | disclosed |
| EP-2081949-A2 | TRIPARTITE OLIGONUCLEOTIDE COMPLEXES AND METHODS FOR GENE SILENCING BY RNA INTERFERENCE | Dharmacon, Inc. (US) | 2009-07-29 | — | — | EP | disclosed |
| EP-2064223-A2 | DUPLEX OLIGONUCLEOTIDE COMPLEXES AND METHODS FOR GENE SILENCING BY RNA INTERFERENCE | Dharmacon, Inc. (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20080085869-A1 | Sense strand, antisense strand having complementarity to both the sense strand and a target gene, forming a duplex, a conjugate, facilitating cellular delivery, and a linker molecule; facilitates delivery to a cell, tissue or organism | DHARMACON, INC. (US) | 2008-04-10 | — | — | US | disclosed |
| WO-2008036825-A2 | DUPLEX OLIGONUCLEOTIDE COMPLEXES AND METHODS FOR GENE SILENCING BY RNA INTERFERENCE | DHARMACON, INC. (US) | 2008-03-27 | — | — | WO | disclosed |
| WO-2008036841-A2 | TRIPARTITE OLIGONUCLEOTIDE COMPLEXES AND METHODS FOR GENE SILENCING BY RNA INTERFERENCE | DHARMACON, INC. (US) | 2008-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093085-A1 | TRIPARTITE OLIGONUCLEOTIDE COMPLEXES AND METHODS FOR GENE SILENCING BY RNA INTERFERENCE | SNRPE, DCLRE1B, RNASE1 | SLC6A11 4048/4885SLC6A1 3955/4885KIF11 1907/4885 |
| US-20080085869-A1 | Sense strand, antisense strand having complementarity to both the sense strand and a target gene, forming a duplex, a conjugate, facilitating cellular delivery, and a linker molecule; facilitates delivery to a cell, tissue or organism | SRRT, SNRPE, SSBP1 | SLC6A11 4167/4885SLC6A1 4057/4885KIF11 1543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.